Miss a day, and you have a gap in coverage
GLP-1 Receptor Activation This is the same pathway used by Semaglutide (Ozempic, Wegovy): Suppresses appetite via hypothalamic signaling Delays gastric emptying , prolonging fullness Improves insulin secretion and glucose control Lowers postprandial glucose and insulin resistance GIP Receptor Activation Shared with Tirzepatide, GIP provides several synergistic effects: Enhances insulin release in response to meals May reduce GI side effects (like nausea) seen with GLP-1s alone Potentially improves lipid metabolism and adipose tissue response Glucagon Receptor Activation This is where Retatrutide takes a leap beyond dual agonists: Increases energy expenditure and fat oxidation Mobilizes stored fat through hepatic lipolysis May preserve or enhance lean mass during weight loss Supports brown fat activation and thermogenesis The addition of glucagon receptor activation to GLP-1 and GIP may enhance fat oxidation and energy burn beyond whats seen with dual agonists. Coskun et al., Cell Metabolism Together, these pathways work synergistically: GLP-1 blunts hunger , GIP improves insulin dynamics , and glucagon turns up fat-burning efficiency
10 mg tirzepatide vial The 10 mg vial is one of the most popular sizes for researchers following standard tirzepatide dosing protocols
Injuries claimed: Severe gastroparesis (stomach paralysis), ileus (impaired bowel function), intestinal obstruction and permanent vision loss from non-arteritic anterior ischemic optic neuropathy (NAION)
In one study of semaglutide, people with type 2 diabetes lost about 4% of their body weight after three months of taking semaglutide
The researchers reported telomere-length changes through telomerase-related or alternative-lengthening pathways depending on the cell line
